MeSH D054559 - hyperphosphatemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | Sevelamer | Sevelamer | 2019-02-08 | |||
| Cipla | Sevelamer | Sevelamer | 2017-10-26 | |||
| Lupin Research | Sevelamer | Sevelamer | 2021-12-23 | |||
| Chartwell Pharmaceuticals | Sevelamer | Sevelamer | 2021-01-14 | |||
| Sanofi | Sevelamer | Renagel | 1998-10-30 | |||
| Sevelamer | Renvela | 2025-10-27 | 2007-10-19 | |||
| Sevelamer | Sevelamer Winthrop (previously Sevelamer Zentiva) | 2015-01-15 | ||||
| Sevelamer | Tasermity | 2015-02-25 | ||||
| Aurobindo Pharma | Sevelamer | Sevelamer | 2017-07-17 | |||
| Dr Reddys Laboratories | Sevelamer | Sevelamer | 2017-09-29 | |||
| Rising Pharmaceuticals | Sevelamer | Sevelamer | 2020-12-14 | |||
| Zydus Therapeutics | Sevelamer | Sevelamer | 2020-08-11 | |||
| Amneal Pharmaceuticals | Sevelamer | Sevelamer | 2017-11-28 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
71%5/7
Phase 2
86%12/14
Phase 3
94%15/16
Approved: 4Overall Success rate: 57%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use